Clinical reference Biomarker Directory
Back to directory

G6PD

Established

G6PD deficiency causes drug/food-triggered hemolytic anemia; testing is required before certain antimalarial drugs.

Also known as G6PD deficiency favism
In plain language

G6PD is a red blood cell enzyme. People who lack enough of it can develop dangerous anemia if they take certain medications, especially some malaria drugs. Testing before treatment prevents this, and newer, simpler malaria drugs require even more precise testing to be used safely.

Biomarker & context

Glucose-6-phosphate dehydrogenase (G6PD) is a red blood cell enzyme protecting against oxidative stress; its genetic deficiency, one of the most common enzyme deficiencies worldwide, causes hemolytic anemia triggered by certain drugs, infections, or foods (fava beans).

What it indicates

G6PD-deficient individuals are at risk of acute hemolysis when exposed to oxidative drugs, most notably antimalarial medications (primaquine, tafenoquine), certain antibiotics, and fava beans; testing before prescribing these drugs prevents dangerous, sometimes fatal, hemolytic episodes.

Diagnosis & clinical testing

Screened via quantitative or qualitative enzyme activity assay; tafenoquine, a newer single-dose antimalarial, requires quantitative G6PD testing (stricter than primaquine's simpler qualitative threshold) before prescribing, since its longer half-life makes hemolysis more dangerous in deficient patients.

Guiding treatment

Countries like Brazil have been actively rolling out point-of-care quantitative G6PD screening specifically to enable safer, simpler single-dose malaria treatment with tafenoquine; patients with confirmed deficiency should avoid known oxidative triggers indefinitely.

Clinical significance

Newer antimalarials (tafenoquine) require stricter quantitative testing than older drugs due to greater hemolysis risk.

References
  1. MMWR/CDC. (2019, ongoing guidance). Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria.
  2. PMC. (2025). The cost-effectiveness of tafenoquine following screening with STANDARD G6PD screening in Brazil.